Historically, children with food allergies have been treated through strict avoidance of the allergen. Recently, an oral preparation of peanut allergen was approved for immunotherapy in children 4 to 17 years old.
In early 2020, the FDA approved Palforzia, an oral immunotherapy drug designed to control allergic reactions to peanut allergies. Sandra Hong, MD, Director of Cleveland Clinic’s Food Allergy Center of Excellence, the first in northern Ohio, discusses the clinical implications for this new treatment.
A new oral immunotherapy drug for peanut allergies will be the No. 4 most influential medical innovation for 2020, predict experts at Cleveland Clinic.
Recent developments in immunotherapy mean that patients with peanut allergies have more options than ever before. Pediatric allergist, Dr. Jacyln Bjelac explains these developments and introduces two peanut oral immunotherapy trials.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
What’s new in managing children with food allergies? Pretty much everything. Brian Schroer, MD, explains.